A CS1-NKG2D bi-specific antibody, containing an anti-CS1scFv and an anti-NKG2D scFv, displayed a dose-dependent increase in specific cytotoxicity of NK cells as well as cytokine production in vitro, and significantly prolonged survival in a human multiple myeloma (MM) model (61). The gene discussed is KLRK1; the disease is Miyoshi myopathy.